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Abstract
Background: Indigenous Australians have an incidence of end stage kidney disease 8-10 times higher than non-
Indigenous Australians. The majority of research studies concerning Indigenous Australians have been performed in
rural or remote regions, whilst the majority of Indigenous Australians actually live in urban settings. We studied
prevalence and factors associated with markers of kidney disease in an urban Indigenous Australian cohort, and
compared results with those for the general Australian population.
Methods: 860 Indigenous adult participants of the Darwin Region Urban Indigenous Diabetes (DRUID) Study were
assessed for albuminuria (urine albumin-creatinine ratio≥2.5 mg/mmol males, ≥3.5 mg/mmol females) and low
eGFR (estimated glomular filtration rate < 60 mls/min/1.73 m2). Associations between risk factors and kidney
disease markers were explored. Comparison was made with the AusDiab cohort (n = 8,936 aged 25-64 years),
representative of the general Australian adult population.
Results: A high prevalence of albuminuria (14.8%) was found in DRUID, whilst prevalence of low eGFR was 2.4%.
Older age, higher HbA1c, hypertension, higher C-reactive protein and current smoking were independently
associated with albuminuria on multiple regression. Low eGFR was independently associated with older age,
hypertension, albuminuria and higher triglycerides. Compared to AusDiab participants, DRUID participants had a 3-
fold higher adjusted risk of albuminuria but not of low eGFR.
Conclusions: Given the significant excess of ESKD observed in Indigenous versus non-Indigenous Australians, these
findings could suggest either: albuminuria may be a better prognostic marker of kidney disease than low eGFR;
that eGFR equations may be inaccurate in the Indigenous population; a less marked differential between
Indigenous and non-Indigenous Australians for ESKD rates in urban compared to remote regions; or that
differences in the pathophysiology of chronic kidney disease exist between Indigenous and non-Indigenous
populations.
Background
Indigenous Australians have an incidence of end stage
kidney disease (ESKD) 8-10 times higher than non-Indi-
genous Australians and life expectancy 15-20 years
shorter [1-3]. Whilst ESKD rates are very high amongst
Indigenous Australians overall, they vary widely across
Australia, with a 20-30 fold gradient reported, and a
strong link to socioeconomic status [4]. Type 2 diabetes
is the leading cause of ESKD in Indigenous Australians:
61% of new ESKD in Indigenous Australians was
attributed to diabetes in 2005 compared to 28% in non-
Indigenous Australians [5].
Fewer data are available about chronic kidney disease
(CKD) amongst Indigenous Australians. Torres Strait
data show that 40% of people on a local diabetes register
have CKD (estimated glomerular filtration rate, eGFR,
<60 mls/min/1.73 m2) [6]. Albuminuria rates are very
high amongst Indigenous Australians [5,7-9] and are
associated with components of the metabolic syndrome
[7,8], predictive of kidney failure, all-cause mortality
[10], and incident coronary heart disease [11].
Cigarette smoking has been associated with CKD pro-
gression in diabetes [12], and smoking rates among Indi-
genous Australians range from 50-70% [7,9,13].
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Most studies of Indigenous Australians concern those
living in rural and remote regions; less is known about
patterns of kidney damage in urban areas, where the
majority of Indigenous Australians live [14]. The Darwin
Region Urban Indigenous Diabetes (DRUID) Study was
designed to address this knowledge gap. The aims of this
paper are to: (i) describe the prevalence of markers of
kidney disease (albuminuria, low eGFR); (ii) determine
what demographic and biomedical factors are associated
with these markers; and (iii) compare risk of albuminuria
and low eGFR in DRUID with that of a representative
cohort of the general population from the Australian Dia-
betes Obesity and Lifestyle (AusDiab) study.
Methods
Participants
The DRUID Study was a cross-sectional study of
approximately 1,000 urban Indigenous people from Dar-
win, Australia, undertaken from September 2003 to
March 2005. The population, methods and response
rates have been previously described [15]. DRUID parti-
cipants met the following eligibility criteria: identified as
Aboriginal and/or Torres Strait Islander; aged≥15 years;
had resided within a specified geographical region
around Darwin for at least six months; and living in a
private dwelling. All participants underwent a 75 gm
oral glucose tolerance test (OGTT) unless pregnant or
on medications for diabetes. The DRUID study was a
volunteer cohort including approximately 14% of the
estimated target population, and therefore not necessa-
rily representative of the target population.
Assessment of albuminuria and low eGFR
For both the albuminuria and low eGFR analyses, 860
participants provided blood and urine samples and did
not have a urinary tract infection confirmed by urine
microscopy and culture (Figure 1). A morning spot
urine sample was performed. Dipstick testing of urine
was introduced a few months after the study began [15]
and was performed on all subsequent samples. Those
with 1+ or greater for blood (or leucocytes or nitrites)
were asked to provide a midstream urine sample (MSU).
Of 197 participants requiring an MSU, 164 (83%) pro-
vided one. Participants with indeterminate results ("pos-
sible contamination, no significant growth”) on MSU (n
= 33) and those with no dipstick testing (n = 233) were
included in the analysis.
Microalbuminuria was defined as urine ACR ≥2.5 and
≤25 mg/mmol in men and ≥3.5 and ≤25 mg/mmol in
women. Macroalbuminuria was defined as ACR > 25
mg/mmol. Albuminuria was defined as ACR ≥2.5 mg/
mmol in men and ≥3.5 mg/mmol in women [16].
Serum creatinine was measured by kinetic Jaffe reac-
tion (Hitachi 917 instrument) by the Clinical Trials
Laboratory, Flinders Medical Centre, prior to the intro-
duction of creatinine assays traceable to the interna-
tional reference method of Isotope Dilution Mass
Spectrometry (IDMS). Low eGFR was defined as eGFR
< 60 mls/min/1.73 m2, corresponding to CKD stage 3-5.
eGFR was calculated using the “186” MDRD (modifica-
tion of diet in renal disease) formula (for creatinine
measurements not calibrated to IDMS) [17]. Of note,
the MDRD formula has not been validated in Indigen-
ous Australians [17,18]. However in the absence of any
validated measure of GFR in this population, MDRD is
currently recommended (without adjustment for “Afri-
can American”) [18]. Creatinine clearance was calculated
using the Cockcroft-Gault formula, adjusted for body
surface area (DuBois formula); neither Cockcroft-Gault
nor Dubois formulae have been validated in Indigenous
Australians.
Anthropometry, blood pressure and biochemistry
Other measures were performed as described previously
[15,19]. Diabetes diagnosis was based on OGTT, using
the 1999 WHO diabetes classification [20]. High blood
pressure was defined as systolic BP ≥ 140 mmHg or dia-
stolic BP ≥ 90 mmHg or participant currently taking
antihypertensive medications. C-reactive protein (CRP)
was included as both an inflammatory marker (infection
has been associated with albuminuria in Indigenous
Australians [7]) and a factor associated with metabolic
risk (it clusters closely with metabolic syndrome features
in Indigenous Australians [21]). The metabolic syn-
drome was defined according to the National Choles-
terol Education Panel (NCEP-ATPIII) [22].
Comparability of DRUID and AusDiab methods
As previously described [23], the AusDiab study was a
population-based survey in 1999-2000 of 11, 247 adults
aged ≥25 years residing in randomly selected urban and
rural areas of Australia. Methods for DRUID and Aus-
Diab were comparable with some minor exceptions, out-
lined in Table 1. As with DRUID participants, AusDiab
participants with confirmed urinary tract infection (n =
302) were excluded from analysis.
Statistical Analysis
Data analysis was performed using STATA v10.0 (Stata
Corporation, TX, USA). Variables with distributions sig-
nificantly different from normal were log transformed
(natural log). Data are presented as mean (standard
deviation) or geometric mean (95% confidence interval).
Participant characteristics are presented by gender and
comparisons were made between genders using Pearson
chi-square tests (categorical variables) or independent
sample t-tests (continuous variables). Univariate analysis
was performed between variables outlined in Table 2
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DRUID Study participant
n=1004
Not included No Provided
i l ?n=94
Yes (n = 910)











Included in analysisHad UTINot included Yes No*
es n = 
n=860on MSU?n=12
* Includes those with no MSU and 
those with no dipstick testing
Figure 1 Flow diagram of included DRUID participants.




Dinamap semi-automatic oscillometric recorder Welch Allyn Spot Vital signs monitor
HbA1c* Boronate affinity high-performance liquid chromatography
(BioRad Variant Haemoglobin Testing System, BioRad, Hercules,
CA, USA)
Percentage of total haemoglobin after separation by ion-exchange




Modified Jaffe reaction (Olympus AU600 auto-analyser)** Kinetic Jaffe (Hitachi 917)
eGFR Estimated from calibrated serum creatinine values, using the
“175” MDRD equation




Immunonephelometry (Beckman Array) Immunonephelometry (Beckman array 360)
Urine
creatinine
Modified Jaffe reaction (Olympus AU600 auto-analyser) Kinetic Jaffe (Hitachi 917)
CRP Data unavailable, therefore CRP not included in comparative
model
* Comparison of 53 samples by both HbA1c methods: mean HbA1c 5.94% (Pharmacia) vs 6.33% (BioRad), r = 0.972, p < 0.001, Bland-Altman mean difference
0.396 (95%CI 0.309-0.483), p = 0.027 (Pitman’s).
**subsequent calibration to IDMS method by re-assaying a stored sub sample (n = 241)
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and markers of renal damage using logistic regression
and unadjusted odds ratios reported. Established risk
factors and variables identified in univariate analyses
were then included in backward stepwise logistic
regression models for albuminuria and low eGFR. Pos-
sible interactions were assessed between categorical
variables of hypertension and albuminuria as well as
hypertension and smoking status. Goodness of fit was
assessed using likelihood-ratio tests to compare nested
models; a significance level of p < 0.05 was used. Pre-
valence rates and 95% binomial confidence intervals of
albuminuria and renal impairment are presented strati-
fied by age group and gender for both DRUID and
AusDiab participants. Pearson’s chi-square test was
used to compare prevalence rates of albuminuria and
renal impairment between DRUID and AusDiab parti-
cipants stratified by age group and gender. Data for
DRUID and AusDiab participants aged 25-64 years
were combined for further analysis to allow for adjust-
ment of differences such as age distribution. Univariate
associations between variables and logistic regression
analysis were then performed for the combined dataset
in the same manner as above.
Ethical Approval
Ethics approval was given by the combined Human
Research Ethics Committee of Northern Territory
Department of Health and Community Services and
Menzies School of Health Research, Darwin. This
included review by both the Aboriginal Sub-Committee
and the main committee.
Results
Characteristics of DRUID participants are outlined in
Table 2. Albuminuria was present in 14.8% (n = 127) of
participants: microalbuminuria 10.5% (n = 90) and
macroalbuminuria 4.3% (n = 37). There was no signifi-
cant difference in albuminuria between genders.
Albuminuria prevalence was lowest for participants
with neither diabetes nor metabolic syndrome (8.0%)
and rose steadily: metabolic syndrome (23.3%, p < 0.001
vs those without metabolic syndrome), diabetes only
(27.9%), both diabetes and metabolic syndrome (33.6%).
This gradient remained after adjustment for age and
gender (data not shown).
Low eGFR was present in 2.4% (n = 21), with no sig-
nificant difference between genders. A similar preva-
lence of renal impairment (2.0%) was observed using the
Cockcroft-Gault formula adjusted for body surface area.
Significant univariate associations with albuminuria
(unadjusted odds ratio and 95% CI) in DRUID partici-
pants were: age, 1.04 (1.03-1.06); waist circumference,
1.02 (1.01-1.04); waist-hip ratio, 212 (32-1406); mean
systolic blood pressure, 1.05 (1.03-1.06); mean diastolic
blood pressure, 1.07 (1.05-1.09); HbA1c, 1.6 (1.4-1.8);
total cholesterol, 1.3 (1.1-1.5); HDL cholesterol, 0.3 (0.1-
0.5); diabetes, 4.0 (2.9-6.1); current smoker, 1.5 (1.0-2.3);
and the following log-transformed variables: triglycer-
ides, 2.4 (1.8-3.3) and CRP, 1.6 (1.3-1.9). Significant uni-
variate associations with renal impairment were: age,
1.08 (1.05-1.11); waist circumference, 1.03 (1.00-1.05);
waist-hip ratio, 1243 (33-47468); mean systolic blood
pressure, 1.05 (1.03-1.07); mean diastolic blood pressure,
1.06 (1.02-1.10); HbA1c, 1.5 91.2-1.8); HDL cholesterol,
0.1 (0.0-0.6); albuminuria, 8.9 (3.7-21.7); diabetes, 5.8
(2.5-13.5); and the following log transformed variables:
triglycerides, 4.0 (2.4-6.8); CRP, 1.9 (1.3-2.7).
On multiple regression analysis (Table 3), only older
age, higher HbA1c, hypertension, current smoking and
higher CRP were significantly associated with albumi-
nuria. Older age, hypertension, albuminuria and higher
triglycerides were significantly associated with low
eGFR, and there was a significant negative interaction (p
= 0.015) between hypertension and albuminuria. Hyper-
tension was an important risk factor for low eGFR only
in participants without albuminuria; those with albumi-
nuria had high risk of low eGFR regardless of whether
hypertension was present.
Table 2 Characteristics of DRUID participants by gender
Male (n = 274) Female (n = 586)




Current smoker: 43% 43%
Type 2 Diabetes (%) 15.3% 19.5%
Height (cm) 174.1 ± 7.1 161.9 ± 6.1†
Weight (kg) 84.0 ± 19.8 75.1 ± 20.0†
BMI (kg/m2) 27.6 ± 5.8 28.6 ± 7.5**
Waist (cm) 96.7 ± 15.3 93.6 ± 17.1**
WHR 0.95 ± 0.08 0.88 ± 0.10†
SBP (mmHg) 121.4 ± 15.4 114.8 ± 16.4†
DBP (mmHg) 75.2 ± 11.1 72.9 ± 9.6**
Total chol (mmol/L) 5.2 ± 1.3 4.9 ± 1.0†
HDL chol (mmol/L) 1.06 ± 0.30 1.19 ± 0.34†
LDL chol (mmol/L) 3.15 ± 1.01 3.02 ± 0.84
Triglycerides (mmol/L)* 1.77 (1.64-1.92) 1.37 (1.31-1.43) †
HbA1c (%)* 5.58 (5.45-5.71) 5.58 (5.50-5.67)
CRP (mg/L)* 2.36 (2.05-2.72) 3.63 (3.28-4.10) †
Urine ACR(mg/mmol)* 0.73 (0.60-0.88) 0.95 (0.85-1.07)**
eGFR (ml/min/1.73 m2)* 93 (91-96) 95 (93-97)
Results are mean ± standard deviation unless stated otherwise
BMI, body mass index; WHR, waist-hip ratio; SBP, systolic blood pressure; DBP,
diastolic blood pressure; chol, cholesterol; CRP, c-reactive protein.
Number of participants with missing data: height - 22; weight - 27; BMI - 28;
waist - 41; WHR - 42; LDL cholesterol - 35. *Geometric mean (95% confidence
interval)
**p < 0.05 between genders
†p < 0.001 between genders
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A comparison between DRUID and AusDiab partici-
pants for rates of markers of kidney damage by age
group is presented in Table 4; excess albuminuria is
seen in DRUID across all age groups. Table 5 presents
results of multiple regression analysis for the two stu-
dies. After adjusting for other factors, being a DRUID
participant was associated with a 3.2-fold greater risk of
albuminuria but no significant increase in risk of low
eGFR. The AusDiab study included <2% Indigenous
participants (n = 116), and their inclusion or exclusion
made no impact on DRUID-AusDiab comparisons (data
not shown).
Discussion
Consistent with previous reports from remote Indigen-
ous communities [7-9], we observed high rates of albu-
minuria (14.1%) in this urban Indigenous cohort. An
unexpected finding in this study was the very low rate
of low eGFR (2.4%), despite high rates of albuminuria.
Compared with the general Australian population (Aus-
Diab) and after adjustment for other risk factors,
DRUID participants displayed a three-fold greater risk
of albuminuria but not of low eGFR.
The relatively low rate of low eGFR is seemingly at
odds with the higher rates of incident ESKD in Indigen-
ous versus non-Indigenous Australians [1,2], but is con-
sistent with previous observations from two remote
communities in northern Australia: 53.1% albuminuria
and 6.8% renal impairment (assessed by Cockcroft-Gault
formula) in one community [10,24], and 44% albumi-
nuria and 12% renal impairment (MDRD < 60 ml/min/
1.73 m2) in another community [25]. Thus in both
DRUID and two remote Indigenous studies, the propor-
tion of participants with albuminuria was several-fold
higher than the proportion with low eGFR, whereas the
converse was seen in AusDiab. That the ratio of albumi-
nuria to low eGFR is greater in Indigenous than non-
Indigenous Australians is also consistent with findings
of the NEFRON Study (Australian primary care) [26]
and a recent report comparing First Nations People to
other residents of Saskatchewan, Canada [27].
This discrepancy may reflect the different profiles of
the Indigenous and general Australian groups with
respect to age, disorders associated with insulin
Table 3 Final model of independent associations with albuminuria (ACR≥2.5 mg/mmol in men, ≥3.5 mg/mmol in
women) and renal impairment (eGFR < 60 ml/min/1.73 m2) in DRUID participants (n = 860)
Albuminuria OR† (95% CI) Renal Impairment OR† (95% CI)
Age (years) 1.01 (1.00-1.03) 1.05 (1.01-1.10)
HbA1c (%) 1.33 (1.15-1.54) -
High BP 2.62 (1.54-4.47) -
Albuminuria with high BP** - 12.94 (2.33-71.7)
Albuminuria without high BP** - 14.8 (2.75-80.0)
High BP without albuminuria** - 8.24 (1.54-44.1)
No albuminuria, no high BP** - 1.0
Triglycerides (mmol/L) * 3.03 (1.52-6.04)
CRP (mg/L)* 1.22 (1.01-1.49)
Non-smoker -
Ex-smoker 0.88 (0.47-1.64)
Current smoker 1.79 (1.06-3.01)
*log transformed
†Adjusted for all variables for which an estimate is shown
**n = 54 for albuminuria with high BP, 73 for albuminuria without high BP, 107 for high BP without albuminuria and 626 without albuminuria without high BP.
Table 4 Prevalence (% and 95%CI) of albuminuria and
renal impairment by age group and gender in DRUID
and AusDiab participants
DRUID AusDiab
M F M F
Albuminuria*
15-24 years 5.3 (1-13) 5.8 (3-11) - -
25-34 years 3.6 (1-12) 12.4 (7-19) 2.2 (1-4) 3.1 (2-5)†
35-44 years 23.9 (14-36) 11.9 (7-18) 3.6 (3-5) † 3.3 (2-4) †
45-54 years 22.9 (12-37) 25.2 (17-35) 4.6 (4-6) † 5.0 (4-6) †
55-64 years 33.3 (15-57) 21.6 (11-35) 10.0 (8-12)** 5.4 (4-7) †
65-74 years 33.3 (4-77) 28.0 (12-49) 16.5 (14-19) 9.3 (8-12)**
Renal
Impairment*
15-24 years 0 0 - -
25-34 years 0 0.8 (0-4) 0.2 (0-1) 0.6 (0-1)
35-44 years 3.0 (0-10) 0.7 (0-4) 0.7 (0-1) 1.3 (1-2)
45-54 years 6.3 (0-17) 5.6 (2-12) 2.8 (2-4) 5.4 (4-7)
55-64 years 9.5 (1-30) 7.8 (2-19) 4.7 (3-6) 9.6 (8-11)
65-74 years 16.7 (0-64) 4.0 (0-20) 18.0 (15-21) 27.3 (24-31)**
*DRUID n = 76,139; 56,129; 67,135; 48,107; 21,51; 6,25. AusDiab n = 585,775;
1086,1417; 1337,1488; 912,1027; 723,772. (for men, women respectively for
each age group in ascending order)
**p < 0.05, †p < 0.001: for AusDiab compared to DRUID participants of the
same gender for each age group
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resistance, rates of diabetes or obesity-related hyperfiltra-
tion, origins and pathophysiology of kidney disease and
speed of progression through CKD stages [25]. However
it also raises questions regarding the appropriateness of
the MDRD formula (or Cockcroft-Gault formula
+/-adjustment for body surface area) to estimate GFR in
this population. Creatinine-based formulae have several
limitations, including lack of validation in ethnic popula-
tions apart from Caucasians and African Americans; sig-
nificant differences in eGFR and reference GFR have
been reported in a Chinese population (eGFR overesti-
mated reference GFR when GFR < 30 mls/min/1.73 m2)
[28]. Differences in body build and body composition
between Indigenous and non-Indigenous Australians
suggest that eGFR may under-estimate risk for Indigen-
ous Australians [29]. It is possible that the relatively low
rate of reduced eGFR in DRUID is attributable to sam-
pling bias; however, this is inconsistent with our findings
that rates of albuminuria are raised as expected.
As noted above, the prevalences of markers of kidney
disease are generally lower than those previously
reported in remote Indigenous communities (of similar
age profile, ACR≥3.4): 14% albuminuria in DRUID com-
pared to 28% in the Torres Strait and Northern Penin-
sula area [9], 38% in Central Australia [8], and 53% in
the Top End [10]. These observations are consistent
with the reported rates of ESKD, higher in remote than
urban regions, associated with greater socio-economic
disadvantage in remote communities [30]. Higher rates
of diabetes in remote communities may also impact the
rates of albuminuria across different Indigenous cohorts.
Given this apparent urban-remote gradient, it is possible
that rates of ESKD in the Darwin urban region are not
disproportionately higher than non-Indigenous Australia
and that much of the adverse prognosis associated with
albuminuria is displayed as excess cardiovascular rather
than renal risk.
The three-fold greater risk of albuminuria in DRUID
participants is consistent with previous reports compar-
ing Aboriginal and European Australians [31,32]. Predic-
tors of albuminuria and of low eGFR in DRUID were
similar to those in AusDiab [16,33], with the addition of
CRP for albuminuria and triglycerides for low eGFR.
High CRP levels have been reported in other studies of
Indigenous Australians and are strongly related to cen-
tral fat, particularly in women [34]. Measures of glycae-
mia or metabolic syndrome were independent predictors
of albuminuria and low eGFR in DRUID participants,
highlighting the importance of disorders associated with
insulin resistance, and that albuminuria is a likely early
manifestation of these disorders, as previously suggested
by Hoy et al. [35]. Albuminuria’s contribution to low
eGFR in DRUID is consistent with Hoy et al.’s report of
an inverse cross-sectional relationship between urine
ACR and rate of loss of GFR and of baseline ACR as
the most powerful predictor of longitudinal loss of renal
function in a remote Northern Territory Indigenous
community [24]. Indeed, albuminuria appears to be a
superior predictor of accelerated GFR loss in European
populations [36] and is consistent with higher ESKD
rates in Indigenous versus non-Indigenous Australians.
It is possible that higher rates of albuminuria in DRUID
may contribute to accelerated loss of GFR in this group;
this rapid GFR loss may contribute to difficulty captur-
ing such individuals in a cross-sectional study.
Limitations
Our study has several limitations: the DRUID study is
cross-sectional and composed of volunteers (two-thirds
female). The low eGFR as reported in this manuscript
may not be an accurate marker of CKD: GFR was esti-
mated from a serum creatinine assay which was per-
formed prior to the IDMS tractable standard, was
measured only once using a different assay to that
Table 5 Final logistic regression models for renal impairment (eGFR < 60 ml/min/1.73 m2) and albuminuria (ACR≥2.5
mg/mmol in men, ≥3.5 mg/mmol in women): AusDiab and DRUID participants (aged 25-64 years), showing odds ratios
for the variable “Druid vs AusDiab participant” for each outcome
Druid vs AusDiab participant Other variables included in final model**




Renal impairment (n =
8,936)
0.91 (0.57-1.46) 0.77 (0.44-1.36) Age, gender, systolic BP, ACR, smoking status, triglycerides, BMI≥25
Albuminuria (n = 8,918) 4.24 (3.36-5.34) 3.17 (2.39-4.19) Age, gender, high BP, waist circumference, triglycerides, smoking
status
OR, odds ratio; BP; blood pressure; ACR, albumin-creatinine ratio.
Hosmer-Lemeshow test of goodness of fit: renal impairment p = 0.708; albuminuria p = 0.03.
*adjusted for other variables in final model (as listed for each outcome in final column)
**The following variables were considered for inclusion in the final model: age (10 year age group), gender, weight, BMI, waist, waist-hip ratio, BMI≥25 kg/m2,
current smoker, high blood pressure, HbA1c, total cholesterol, triglycerides, urine ACR, and the interaction of high blood pressure and ACR. Variables with p <
0.05 were included in the final model.
§Unadjusted OR includes only those participants who had complete data for variables listed in the final model
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utilised in AusDiab. The MDRD study equation used to
estimate the GFR has not been validated in Indigenous
Australians. A limitation of defining “low eGFR” is that
those with pathologically high eGFR (hyperfiltration) are
not in that group; differences in the rates of obesity or
diabetes-related hyperfiltration between DRUID and
AusDiab may have contributed to the discrepancy in
our findings and warrant further study. The high rate of
albuminuria but not of low eGFR may be due to the
high rates of vascular and metabolic risk factors in the
volunteer DRUID cohort; although factors such as raised
triglycerides, central obesity and hypertension were
included in the models, confounding by unmeasured
factors is possible. Despite such limitations, these data
represent the best currently available data for an urban
Indigenous population in Australia. This is particularly
important given that 73% of the total Indigenous popu-
lation of Australia live in urban centres [14].
Conclusions
We have reported high rates of albuminuria but not of
low eGFR in this urban Indigenous Australian cohort.
Given the high rates of ESKD observed in Indigenous
versus non-Indigenous Australians, possible explanations
of our findings include: (i) albuminuria may be a better
predictor of ESKD in urban indigenous populations than
low eGFR, as is becoming evident in other populations;
(ii) shortfalls exist in the current equations when used
to estimate GFR in Indigenous populations; (iii) a less
marked differential between Indigenous and non-Indi-
genous Australians for rates of ESKD in urban com-
pared to remote regions; or (iv) differences in CKD
pathophysiology between Indigenous and non-Indigen-
ous Australians. There is an urgent need for future
work (including longitudinal studies and eGFR valida-
tion study [37]) to determine which or which combina-
tions of these potential mechanisms explain the high
rates of albuminuria but not of low eGFR in a popula-
tion at high risk of ESKD.
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